Caplin Point Laboratories informs about press release
Caplin Point Laboratories has informed that it enclosed a Press Release regarding receipt of final approval by Subsidiary, Caplin Steriles, from the United States Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Milrinone Lactate in 5% Dextrose Injection, 20 mg/100 mL (0.2 mg/mL) and 40 mg/200 mL (0.2 mg/mL) Single-dose Infusion Bags, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) PRIMACOR in Dextrose 5%, by Sanofi Aventis US LLC.
The above information is a part of company’s filings submitted to BSE.
